CBD, huile de Cannabidiol, THC, médicaments à base de cannabis : le point santé

00:00 Présentation du chanvre et des cannabinoïdes
03:17 Le CBD et propriétés pharmacologiques
05:00 Extraction du CBD
05:30 Huiles de chanvre et CBD
06:52 Composés cancérigènes ?
07:36 Médicaments à base de cannabis
08:35 Effet d'un usage récréationnel du THC/Cannabis sur la santé
09:03 Usage thérapeutique du THC et/ou CBD

► Pour me suivre sur Facebook : https://www.facebook.com/Quoidansmonassiette/
► Pour me suivre sur Twitter : @T_Fiolet https://twitter.com/T_Fiolet
► Mon blog : https://quoidansmonassiette.fr/
Sources :
► Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235-1242. doi:10.1001/jamapsychiatry.2015.1858
► Winters KC, Lee C-YS. Likelihood of developing an alcohol and cannabis use disorder during youth: Association with recent use and age. Drug Alcohol Depend. 2008;92(1-3):239-247.
► Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2(3):244-268. doi:10.1037/1064-1297.2.3.244
►Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1-2):120-130. doi:10.1016/j.drugalcdep.2010.11.004
► VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019;94(9):1840-1851. doi:10.1016/j.mayocp.2019.01.003
► Da Porto C, Decorti D, Natolino A. Potential oil yield, fatty acid composition, and oxidation stability of the hempseed oil from four Cannabis sativa L. cultivars. J Diet Suppl. 2015;12(1):1-10. doi:10.3109/19390211.2014.887601
► ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017;103:1-36. doi:10.1007/978-3-319-45541-9_1
► IARC Assessment. https://monographs.iarc.who.in....t/wp-content/uploads
https://www.mdpi.com/1422-0067/21/18/6740/htm
► White CM. A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential. J Clin Pharmacol. 2019;59(7):923-934. doi:10.1002/jcph.1387
► Li J, Carvajal R, Bruner L, Kaminski NE. The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products. Food Chem Toxicol. 2021;157:112600. doi:10.1016/j.fct.2021.112600
► Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358
► Millar SA, Stone NL, Yates AS, O'Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018;9:1365. Published 2018 Nov 26. doi:10.3389/fphar.2018.01365
► Kröger E, Dionne C E. Medical cannabis for chronic pain BMJ 2021; 374 :n1942 doi:10.1136/bmj.n1942

► INSERM. Cannabinoïdes et système nerveux central : https://www.ipubli.inserm.fr/b....itstream/handle/1060
► https://www.has-sante.fr/uploa....d/docs/evamed/CT-181
► Yin AQ, Wang F, Zhang X. Integrating endocannabinoid signaling in the regulation of anxiety and depression. Acta Pharmacol Sin. 2019;40(3):336-341. doi:10.1038/s41401-018-0051-5
► Australian Therapeutic Goods Administration. Review on the safety of low dose cannabidiol https://www.tga.gov.au/alert/r....eview-safety-low-dos
► https://www.ema.europa.eu/en/d....ocuments/product-inf
► https://www.canada.ca/fr/sante....-canada/services/dro
► Freeman TP, Craft S, Wilson J, et al. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction. 2021;116(5):1000-1010. doi:10.1111/add.15253
► American Cancer Society - Marijuana and Cancer https://www.cancer.org/treatme....nt/treatments-and-si
► Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436. doi:10.1016/S2215-0366(19)30048-3

• Category

  CBD and Cancer Patients